Novel immunosuppressive regimens are now being used in organ transplantation, with the primary aim of reducing therapeutic toxicity and improving patient and allograft survival [1] . Traditionally, calcineurin inhibitor and glucocorticoid-based regimens have been standard, often being complicated by significant short-and long-term morbidity [2, 3] . Such regimens are now being challenged [1, 4, 5] . Alemtuzumab is a humanized monoclonal antibody directed against CD-52, a glycoprotein expressed on B and T lymphocytes, monocytes, and natural killer cells. Profound and sustained lymphocyte depletion is observed after alemtuzumab administration [5] , making it theoretically attractive for use in organ transplantation for the prevention and/or treatment of acute allograft rejection.
Despite the fact that alemtuzumab is approved only for the treatment of B cell lymphocytic leukemia [6] , there now is mounting evidence of its benefits in stem cell [7] and organ transplantation [8] [9] [10] [11] [12] [13] [14] [15] [16] . Calne et al. [4, 14] first reported the effectiveness of administering alemtuzumab at the time of transplantation, also known as induction therapy, for the prophylaxis of acute rejection in renal transplant recipients. Such efficacy data have proved durable after a 5-year follow-up [10] and have now been reproduced elsewhere [15, 17] . Similar, positive results have been reported for other organ types [2, 16, [18] [19] [20] [21] [22] . The use of alemtuzumab for the treatment of steroid-refractory acute allograft rejection has also been successful [9, 23] and is a practice that is now common in many institutions.
Given the potency of alemtuzumab in depleting lymphocytes, there is obvious concern about the risks of infection, particularly with opportunistic organisms. In addition, risks related to oncogenic viruses-in particular, the development of posttransplantation lymphoproliferative disease (PTLD) secondary to infection with Epstein-Barr virus [24, 25] -and infection with emerging allograft-specific viruses, such as BK virus, are potential complications. Such concerns have been well illustrated in the hematology-oncology population, for which rates of infection have ranged from 23% to 79% after alemtuzumab use [26, 27] . Of importance, dosing in this population is significantly greater and more prolonged than is dosing in the organ transplantation population, and most studies include heavily pretreated patients [27] . Thus far, the risks of infection associated with alemtuzumab use in the organ transplantation population appear to be low [28] , but few studies have been performed with the primary purpose of documenting rates of opportunistic infections (OIs), and all include small numbers of patients [28, 29] . Finally, to our knowledge, no study has yet compared the risks of infection relative to the different indications for alemtuzumab in organ transplantation (i.e., induction vs. rejection therapy).
Given the limited literature available, we assessed the infection-related complications in, to our knowledge, the largest number and broadest range of organ transplant recipients yet reported who have received alemtuzumab. Our objectives were (1) to describe the OIs noted in organ transplant recipients receiving alemtuzumab, and (2) to assess the relative infectionrelated risks of alemtuzumab given as induction therapy only, compared with those of alemtuzumab given for acute allograft rejection.
PATIENTS AND METHODS
Patient population. The study was conducted at the University of Pittsburgh Medical Center, a tertiary care institute specializing in organ transplantation, including liver, kidney, heart, lung, pancreas, intestinal, and multivisceral transplantation. Consecutively observed transplant recipients who received alemtuzumab from September 2002 through March 2004 were included in the study. All patients were monitored until death or for 12 months after receipt of their last dose of alemtuzumab. In September 2002, induction therapy with alemtuzumab became standard for all organ transplant recipients, with the exception of heart transplant recipients, at our institution. It was also used for the treatment of steroid-refractory acute allograft rejection. This assessment was approved by the Total Quality Council at the hospital, as a quality improvement initiative.
Clinical data. Data were systematically collected from the computer-based medical archive retrieval system at the hospital. The variables analyzed included age, sex, ethnicity, transplant type, history of previous transplantation, the indication for alemtuzumab, the number of alemtuzumab doses received, use of other immunosuppressive agents, time from receipt of alemtuzumab to infection, time from transplantation to infection, infection type, receipt of prophylaxis at the time of infection, and patient and allograft survival.
Definitions. The primary outcome measure was the occurrence of an OI, which was defined as cytomegalovirus (CMV), Epstein-Barr virus, human herpesvirus 6, or human herpesvirus 7 disease; BK virus or parvovirus infection; esophageal candidiasis; cryptococcosis; invasive mold infection; endemic mycoses; or Pneumocystis jiroveci, mycobacterial, Nocardia, or parasitic infection. PTLD was also considered to be an OI. Definitions for each infection were based on international guidelines [30] [31] [32] [33] . In brief, CMV disease was defined as symptoms and/or signs of an organ-specific illness in conjunction with the detection of CMV in tissue by culture, immunohistochemical analysis, or in situ hybridization [30] . CMV infection, in which replicative virus was detected by pp65 antigenemia in the absence of symptoms, was also assessed but was not included in the end point definition. PTLD was diagnosed on the basis of standard histopathological criteria [34] . Infections with other herpesviruses (herpes simplex virus 1, herpes simplex virus 2, and varicella-zoster virus) were not included because of the lack of objective, microbiological confirmation of such infections for most patients. Bacterial infections (other than Nocardia infection) were not analyzed in the present study.
Alemtuzumab dosing and prophylaxis for infection. At the time of transplantation, a 30-mg dose of intravenous alemtuzumab, given as induction therapy, was administered over 2-3 h. A premedication dose of 1 g of intravenous methylprednisolone was used to minimize the cytokine release syndrome associated with alemtuzumab. This premedication dose was followed by tacrolimus monotherapy, to achieve a trough level of 10 ng/mL or, for lung transplant recipients, a level of 12-15 ng/mL. For treatment of steroid-refractory acute allograft rejection, a single dose (30 mg) of alemtuzumab was used. Rarely, for severe, resistant rejection, multiple doses of alemtuzumab were used. The 12-month follow-up period started from the time of receipt of the last dose of alemtuzumab. Transplant recipients who received alemtuzumab for rejection therapy, either after alemtuzumab induction or as their initial indication, as well as those who received multiple doses for rejection therapy, were analyzed in the rejection therapy group. Other antirejection therapies given before the development of an OI or the end of follow-up were documented, including high-dose methylprednisolone (у1 g), other lymphocyte-depleting antibodies (rabbit antithymocyte globulin [Thymoglobulin] or anti-CD3 monoclonal antibodies [muromonab-CD3 or OKT3]), and the monoclonal IL-2 receptor antibody daclizumab. All available CD4 cell counts were recorded. Lifelong prophylaxis against P. jiroveci was routinely given to all patients, consisting of trimethoprim-sulfamethoxazole (80 mg/400 mg) given orally 3 times per week. Dapsone, pentamidine, or atovaquone was used for sulfa intolerance. Universal CMV prophylaxis with oral valganciclovir was given to kidney, pancreas, and lung transplant recipients for the first 6 months after transplantation. Intravenous ganciclovir was given to intestinal and multivisceral transplant recipients until intestinal absorption was deemed to be adequate. This was followed by therapy with oral ganciclovir to complete a 6-month treatment period. Liver transplant recipients underwent serial CMV surveillance with pp65 antigenemia, and if findings were positive, they were given preemptive therapy. Antifungal prophylaxis with voriconazole was routinely given to liver transplant recipients for the duration of their intensive care unit stay and to lung recipients for the first 4 months after transplantation. Amphotericin B lipid complex was given to intestinal and multivisceral transplant recipients for a variable period. Prophylactic measures were unchanged throughout the study period.
Statistical analysis. Statistical analyses were performed using SAS software, version 8.2 (SAS Institute). ORs and 95% CIs were calculated for binomial variables. Categorical variables were compared using the or Fisher's exact test, as appro-2 x priate. Continuous variables were compared using Student's t test or the Mann-Whitney rank sum test, as appropriate. All variables were analyzed by univariate analysis, and those for which were included in a logistic regression multivariable P ! .2 model, by use of a stepwise technique, to assess for independent predictors of an OI. Variables were assessed for confounding and collinearity. All P values were 2-tailed, and was P ! .05 considered to be statistically significant.
RESULTS
A total of 581 organ transplant recipients received у1 dose of alemtuzumab during the study period. Thirty-four patients were excluded because of an incomplete 12-month follow up; none of the patients who were excluded had developed an OI. The characteristics of the 547 evaluable transplant recipients who were monitored either until death or for 12 months after the administration of alemtuzumab are presented in table 1. The median patient age was 51 years (range, 16-82 years), with 141 patients (26%) у60 years of age. Recipients of all transplant types at our institution, except for heart transplant recipients, were represented ( 
). P p .09 Conversely, the median time to infection after transplantation was longer for persons who received alemtuzumab for rejection therapy (236 days; range, 24-4258 days), compared with that for persons who received alemtuzumab for induction therapy (120 days; range, 30-328 days;
). Of the 56 recipients P p .02 who had an OI, 12 (21%) died, with 7 deaths (12.5%) being attributable to infection. A CD4 cell count obtained within 1 month of the development of infection was available for 25 episodes of infection (40%). The median CD4 cell count was 10 cells/mm 3 (range, 1-210 cells/mm 3 ).
Viral infections. The most common infection was CMV disease (
). The median time to the development of CMV n p 16 disease after alemtuzumab therapy and after transplantation was 85 days (range, 7-254 days) and 145 days (range, 24-2798 days), respectively. Five recipients (31%) developed CMV disease within 100 days of transplantation; 4 of these recipients were liver transplant recipients who were not receiving antiviral therapy, and 1 recipient was an intestinal transplant recipient who was receiving CMV prophylaxis. Of the 16 recipients with CMV disease, 6 (38%) were intestinal or multivisceral transplant recipients, all of whom had CMV enteritis; 4 (25%) were liver recipients, 3 of whom had hepatitis and 1 of whom had enteritis; 3 (19%) were lung recipients, all of whom had pneumonitis; and 3 (19%) were pancreas or pancreas/kidney recipients (1 each had pneumonitis, gastritis, and a febrile viral syndrome). Five transplant recipients (31%) who had CMV disease died, with 2 of these deaths attributable to the infection.
With regard to other viruses, there were 3 cases of EpsteinBarr virus infection manifesting as PTLD (in 2 lung transplant recipients and 1 liver transplant recipient). Two other cases of PTLD were diagnosed in recipients of kidney and multivisceral transplants, but results of in situ hybridization for the detection of Epstein-Barr virus were negative for both recipients. One kidney transplant recipient had human herpesvirus 6 disease, with positive results of PCR analysis of blood and CSF samples for human herpesvirus 6 noted in conjunction with a compatible illness. The patient died within 28 days of diagnosis. Of the 12 kidney recipients who had infection with BK virus (de- fined as any positive result for BK virus DNA on PCR), 6 had BK viruria, 4 had BK viremia and viruria, and 2 had BK viremia. Of these recipients, 3 (25%) had allograft failure at the 12-month follow-up, with 1 having histologically proven BK virus nephropathy. One case of parvovirus infection occurred in a lung transplant recipient who presented with fever and anemia. The diagnosis was confirmed by serological testing and PCR analysis of serum samples.
Invasive fungal infections.
A total of 18 transplant recipients (32%) developed an invasive fungal infection. The median time to infection after alemtuzumab therapy and after transplantation was 58 days (range, 2-265 days) and 242 days (range, 42-2036 days), respectively. The majority (12 transplant recipients [66%]) had esophageal candidiasis. Of the 2 patients who had cryptococcosis, 1 had pulmonary disease and 1 had meningitis. Two patients had invasive fungal sinusitis (infection with Aspergillus species and mucormycosis). Two intestinal transplant recipients had disseminated infection with Scedosporium apiospermum (pulmonary and CNS infection) and Scedosporium prolificans (pulmonary and upper airway infection), respectively, with both recipients dying within 6 weeks of diagnosis as a consequence of their infection. No patient developed P. jiroveci infection.
Nocardia organisms, mycobacteria, and protozoa. Of the 4 patients with Nocardia infection, 3 lung transplant recipients had isolated pulmonary disease, and 1 liver recipient had disseminated disease with positive blood culture results. One kidney transplant recipient developed miliary tuberculosis, and 2 lung transplant recipients had pulmonary infection with Mycobacterium kansasii. Of the parasitic infections, B. mandrillaris meningitis was confirmed at the time of autopsy of 1 multivisceral transplant recipient. This patient died 2 days after receiving alemtuzumab and appeared to have symptoms suggestive of infection prior to alemtuzumab administration. One lung transplant recipient had pneumonia due to Toxoplasma gondii.
Predictors of an OI
Of the 354 recipients who received alemtuzumab for induction therapy only, 16 (4.5%) developed an OI. In contrast, 40 (21%) of the 193 recipients who received у1 dose of alemtuzumab for rejection therapy developed an OI (OR, 5.5; 95% CI, 3.0-
10.0;
). The risk of developing an OI was identical P ! .001 whether a recipient received alemtuzumab as induction therapy and then for the treatment of rejection (8 [22%] of 37 recipients) or as rejection therapy initially (32 [21%] of 156 recipients). Other variables found to be significantly associated with infection on univariate analysis are shown in table 3. Given the timing of B. mandrillaris infection (which occurred 2 days after receipt of alemtuzumab), the analysis was repeated with this episode excluded. The results were unchanged.
Multivariable logistic regression analysis (table 4) demonstrated that independent predictors of the development of an OI were receipt of у1 dose of alemtuzumab for rejection therapy (OR, 3.5; 95% CI, 1.8-6.8;
), development of al-P ! .001 lograft failure (OR, 2.1; 95% CI, 1.1-4.4; ), or receipt P p .04 of a lung transplant (OR, 3.7; 95% CI, 1.7-8.0; ) or P p .001 an intestinal or multivisceral transplant (OR, 8.3; 95% CI, 3.5-19.5;
). Although receipt of a lymphocyte-depleting an-P ! .001 tibody in addition to alemtuzumab was a risk factor on univariate analysis (table 3) , it was not found to be significant on multivariable analysis. In a subgroup analysis of the 193 patients who received у1 dose of alemtuzumab for rejection therapy, no significant difference in the occurrence of OIs was observed for those given another lymphocyte-depleting antibody (n p ), compared with those who received alemtuzumab only 126 ( ) (21% vs. 19%, respectively; ). To analyze n p 67 P p .85 whether CMV antigenemia and/or disease was associated with other OIs, CMV disease was removed from the end point definition of infection. CMV antigenemia and disease were then analyzed as a predisposing variable. On univariate analysis, no significant association was found between CMV and other OIs (OR, 1.1; 95% CI, 0.5-2.5;
). After the multivariable P p .89 analysis was repeated, the same independent predictors for OI were identified, except for allograft failure.
Lymphocyte Depletion after Alemtuzumab Therapy
A total of 291 CD4 cell counts obtained for 109 patients were available for analysis. A significant depletion in the CD4 cell count was observed ( , for all time periods), with a P ! .001 median CD4 cell count of 626 cells/mm 3 noted at baseline, compared with median counts of 6, 15, 52, 92, and 127 cells/ mm 3 noted at 1, 3, 6, 9, and 12 months, respectively, after therapy. Median CD4 cell counts were similar between recipients with or without an OI (table 3) , as well as between recipients who received alemtuzumab for induction or rejection therapy (data not shown).
DISCUSSION
Alemtuzumab, a CD-52 humanized monoclonal antibody, causes potent and durable suppression of T lymphocytes and has proved successful in the prevention and/or treatment of acute allograft rejection in organ transplant recipients [8] [9] [10] 18] . Its use over the past 2 years, since its availability in the United States, has rapidly increased, with up to 43% of pancreas, 19% of intestinal, and 7% of renal transplant recipients receiving it for induction therapy in 2004 and with up to 15% of intestinal transplant recipients receiving it for rejection therapy in 2003 [35] . Given the propensity of alemtuzumab to cause profound lymphocyte depletion, we studied the risks of OIs in what, to our knowledge, is the largest cohort of organ transplant recipients to receive alemtuzumab to date. Our results demonstrate that, when patients receive alemtuzumab for induction therapy only, their risk of developing an OI is low (4.5%). Conversely, patients given у1 dose of alemtuzumab as rejection therapy are nearly 5 times more likely to develop an OI (21%;
).
Several factors may explain this marked difference in the incidence of OIs. First, and most importantly, transplant recipients who receive alemtuzumab for rejection therapy are also exposed to other potent immunosuppressive agents and, therefore, have a significantly greater net state of immunosuppression. In fact, 65% of such patients received another type of lymphocyte-depleting antibody, most commonly rabbit antithymocyte globulin. However, after we adjusted for this confounding variable by use of a multivariable model, receipt of alemtuzumab for rejection therapy remained an independent predictor of infection. It is still possible that other therapies for acute rejection, which were not documented in the present study, such as increases in maintenance immunosuppression, may explain the differences in rates of infection. Second, transplant recipients who received alemtuzumab for rejection therapy were more likely to develop allograft failure than were transplant recipients who did not (27% vs. 7%;
). Such P ! .0001 an outcome may have a negative influence on the immune function of the patient, either directly or indirectly through augmented immunosuppression. Of interest, allograft failure was an independent predictor of an OI (OR, 2.1; 95% CI, 1.1-4.4; ) in our analysis. Third, transplant recipients who P p .04 were given alemtuzumab for rejection therapy were inherently farther out from transplantation, compared with recipients who received alemtuzumab for induction therapy; therefore, the former patients may not have been receiving the same intensive antimicrobial prophylaxis. Our data support this theory, because, for recipients given alemtuzumab for induction therapy, the median time to infection after transplantation was 120 days (range, 30-328 days), compared with a median of 236 days (range, 24-4258 days) for recipients given alemtuzumab for rejection therapy ( ). The latter period is well beyond P p .02 the antimicrobial prophylaxis period at most transplant centers. Finally, was it the immunosuppressive effects of CMV that were confounding the difference in OIs? Our data do not support this theory, because when CMV disease was removed from the end point definition and was included with antigenemia as a predisposing variable, no association with OIs was found ( ) . P p .89
Thus far, the rates of OI after the use of alemtuzumab therapy for organ transplant recipients have been low [8, 15, 16, 20, 28, 29] . Such low rates of OIs in recipients receiving alemtuzumab for induction therapy may have several explanations. These reasons include a reduced requirement for augmented immunosuppression as a result of a reduction in acute rejection [8, 15, 19, 20, 36] , an ability to avoid or minimize exposure to both corticosteroids [16] and calcineurin inhibitors [2, 19] , and the routine prescription of intensive antimicrobial prophylaxis in the early posttransplant period. Also, despite the marked lymphocyte depletion noted after administration of alemtuzumab, the qualitative function of the remaining and slowly recovering lymphocytes may be adequate [37] . Such data highlight the complexity of immunity well beyond a quantitative measurement. Functional T cell assays, which are now US Food and Drug Administration approved and commercially available, may be very useful for the future assessment of immunosuppressive agents in transplantation.
Given the risk of OIs in patients receiving alemtuzumab for the treatment of rejection (21%), antimicrobial prophylaxis may be an important preventative measure. Of the 193 recipients given alemtuzumab for rejection therapy, 12 (6%) developed CMV disease, with 9 (75%) having CMV disease develop within 3 months of receipt of alemtuzumab therapy. Fifteen invasive fungal infections (8%) developed in this subgroup, with 12 (80%) occurring within 3 months of receipt of alemtuzumab therapy. Such data, combined with the fact that these patients are often given alemtuzumab outside of the usual period for antimicrobial prophylaxis, suggest that prophylactic or preemptive strategies (such as CMV monitoring) should be reinstituted for patients who are given alemtuzumab for rejection therapy and that the duration of such prophylaxis should be a minimum of 3 months. Further study is warranted in this area.
Because alemtuzumab was introduced at our institution for routine induction therapy, an appropriate contemporaneous control group was not available for comparison. Therefore, no conclusions can be made about the risks of infection associated with alemtuzumab, compared with those associated with other immunosuppressive regimens. Historical controls were available; however, given the significant limitations inherent in these historical controls, especially in the era of rapidly changing immunosuppressives, antimicrobial prophylaxis, and surgical techniques, it was believed that such a comparison would be fraught with inaccuracies.
In conclusion, alemtuzumab is a novel monoclonal antibody that is being increasingly utilized in organ transplantation for the prophylaxis and/or treatment of acute allograft rejection. Despite its ability to cause impressive lymphocyte depletion, alemtuzumab is associated with surprisingly low risks of an OI developing when it is used only for induction therapy. Conversely, when used for rejection therapy, alemtuzumab is associated with significantly higher risks of an OI, presumably because of the multitude of immunological insults directed at such patients. Thus, when alemtuzumab is used for rejection therapy, close monitoring and a high index of suspicion for OIs are recommended. Also, antimicrobial prophylaxis should be reinstituted if routine posttransplantation prophylaxis has ceased, especially for high-risk transplant recipients, such as lung, intestinal, and multivisceral transplant recipients.
